Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1642]

Study links frailty to five-year mortality rate among older women with breast cancer

Study links frailty to five-year mortality rate among older women with breast cancer

Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report

Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor...

Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19 vaccination, study shows

Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19...

Preventable paediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

Preventable paediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

Digital PCR can reliably determine if chronic myeloid leukeamia patients in remission can successfully discontinue drug treatment

Digital PCR can reliably determine if chronic myeloid leukeamia patients in remission can successfully discontinue...

FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours

FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours

Research discovers a way to slow or block recurrence of glioblastoma

Research discovers a way to slow or block recurrence of glioblastoma

Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy

Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy

Revolutionising protein modification: a new frontier in cancer research

Revolutionising protein modification: a new frontier in cancer research

Efficacy endpoint changes in glioblastoma phase II clinical trials and the factors contributing to these changes

Efficacy endpoint changes in glioblastoma phase II clinical trials and the factors contributing to these changes

More from ecancer